Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Chethan Ramamurthy

6PUBLICATIONS
34CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

Sort by Publication Date:
|Jun 09, 2026
Publisher Correction: Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.

|May 19, 2026
Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.

|Aug 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Daniel P Petrylak, Scott T Tagawa, Rohit K Jain

|Jan 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.

Petros Grivas, Damien Pouessel, Chandler H Park

|Jan 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.

Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes

|Jun 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.

Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak

Pageof 1

Frequent Collaborators

4 joint publications

Daniel P Petrylak

2 joint publications

Jennifer Stuart

2 joint publications

Matthew I Milowsky

2 joint publications

Christopher J Hoimes

2 joint publications

Thomas W Flaig

2 joint publications

Nataliya Mar

2 joint publications

Terence W Friedlander

2 joint publications

Rana R McKay

2 joint publications

Anne-Sophie Carret

2 joint publications

Sergio Bracarda

Frequent Collaborators

4 joint publications

Daniel P Petrylak

2 joint publications

Jennifer Stuart

2 joint publications

Matthew I Milowsky

2 joint publications

Christopher J Hoimes